Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials

Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials

 Programs progressing in line with strategy
 Significant reduction of net loss: ?12.2 million compared to ?28.1 million in H1 2015
 ?33.4 million in cash and cash equivalents as of June 30, 2016
 Cash burn guidance confirmed around ?35 million in 2016

Conference call scheduled in English on September 6th, 2016 at 06:00 PM CET (12:00 PM EST)


Strasbourg, France, September 5, 2016, 5:35 pm CET - Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced its financial results for the six-month period ended June 30, 2016 and published an update on its business and on the development of its portfolio of therapeutic vaccines and oncolytic viruses.
…/…